Natera's Signatera Detects Head and Neck Cancer Recurrence Median 4.3 Months Before Imaging in Study

Bitget2026/11/04 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Natera announced three published, peer-reviewed studies evaluating its Signatera test in head and neck cancer.
Post-surgery testing identified patients likely to benefit from adjuvant chemotherapy; patients testing negative showed no improvement with chemotherapy.
Surveillance testing detected recurrence earlier than imaging across HPV-positive and HPV-negative disease, outperforming clinical risk factors in predicting progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104932386) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Natera's Signatera Detects Head and Neck Cancer Recurrence Median 4.3 Months Before Imaging in Study

You may also like

Crypto prices